Zollinger‑Ellison syndrome diarrhoea - Causes, Treatment & When to See a Doctor

```html

What is Zollinger‑Ellison syndrome diarrhoea?

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to produce large volumes of acid. The hyper‑acidic environment overwhelms the small intestine’s ability to neutralize acid, leading to secretory diarrhoea that is often watery, profuse, and refractory to ordinary anti‑diarrhoeal agents.

While diarrhoea is a hallmark symptom of ZES, it usually occurs together with other gastrointestinal (GI) complaints such as abdominal pain, heartburn, and ulcers. Recognising the pattern of diarrhoea—particularly when it is accompanied by refractory peptic ulcer disease—can prompt earlier diagnosis of the underlying gastrinoma.

Common Causes

Diarrhoea in a patient with ZES can be multifactorial. Below are the most frequent contributors, both directly related to the syndrome and to other co‑existing conditions that can exacerbate the symptom:

• Excess gastric acid secretion – the primary driver of secretory diarrhoea.
• Acid inactivation of pancreatic enzymes – high acidity impairs lipase and protease activity, leading to malabsorption.
• Gastric hypermotility – excess acid can accelerate intestinal transit.
• Peptic ulcer disease (PUD) – ulcer‑related bleeding and inflammation may worsen stool frequency.
• Small‑bowel ulcerations – gastrinomas can cause ulcerations throughout the duodenum and jejunum, increasing fluid loss.
• Medication side effects – high‑dose proton‑pump inhibitors (PPIs) or H2‑blockers can cause constipation, but paradoxically, rapid reduction of acid can precipitate rebound diarrhoea.
• Co‑existing infections – e.g., Clostridioides difficile, especially after antibiotic use for ulcer complications.
• Pancreatic exocrine insufficiency – long‑standing acid damage to the pancreas can reduce enzyme output, producing steatorrhea‑type diarrhoea.
• Small intestinal bacterial overgrowth (SIBO) – acid‑related dysmotility creates an environment for bacterial proliferation.
• Dietary triggers – high‑fat or very spicy foods can further stimulate gastric acid production.

Associated Symptoms

Patients with ZES‑related diarrhoea often report a cluster of GI and systemic findings. Recognising these helps differentiate ZES from more common diarrhoeal illnesses.

• Recurrent or persistent heartburn – due to massive acid load.
• Abdominal pain or cramping – typically epigastric, may radiate to the back.
• Frequent, watery stools – 3–10+ bowel movements per day, often occurring at night.
• Weight loss – from malabsorption and chronic fluid loss.
• Steatorrhea – pale, foul‑smelling, greasy stools when fat malabsorption is present.
• Low serum potassium (hypokalemia) and metabolic alkalosis – result of bicarbonate‑rich intestinal secretions.
• Osteoporosis or bone pain – chronic acid hypersecretion can leach calcium.
• Peptic ulcer disease that is refractory to standard therapy – ulcers in the duodenum, jejunum, or even the stomach that do not heal with PPIs alone.
• Gastric outlet obstruction – from ulcer scarring, leading to nausea and vomiting.

When to See a Doctor

Although occasional loose stools are common, the following warning signs warrant prompt medical evaluation for possible ZES‑related diarrhoea:

• Diarrhoea persisting > 2 weeks despite over‑the‑counter anti‑diarrhoeal medication.
• Stools that are watery, voluminous, and occur ≥ 3 times daily, especially if they worsen at night.
• Unexplained weight loss > 5 % of body weight within a month.
• Severe or worsening heartburn that does not improve with PPIs.
• Abdominal pain that is persistent, worsening, or accompanied by vomiting.
• Signs of dehydration (dry mouth, dizziness, decreased urine output).
• Laboratory evidence of low potassium, low magnesium, or metabolic alkalosis.
• History of peptic ulcer disease that repeatedly relapses despite optimal therapy.

If any of these are present, schedule an appointment with a gastroenterologist or an endocrinologist experienced in neuroendocrine tumors.

Diagnosis

Diagnosing ZES‑related diarrhoea involves confirming both the presence of a gastrinoma and the physiological effects of excess gastrin. The work‑up typically proceeds in three stages: biochemical testing, imaging, and functional assessment.

1. Biochemical Tests

• Fasting serum gastrin level – Levels > 1000 pg/mL (or > 10‑fold the upper limit) are highly suggestive, especially after a secretin stimulation test.
• Secretin stimulation test – Paradoxically, gastrin levels rise after IV secretin in gastrinomas; a rise > 120 pg/mL is diagnostic.
• Gastric pH measurement – A pH < 2 in the fasting state confirms hyper‑acidic environment.
• Electrolytes – Check for hypokalemia, hypomagnesemia, and metabolic alkalosis.

2. Imaging Studies

• Endoscopic ultrasound (EUS) – High‑resolution imaging of the pancreas and duodenum.
• Contrast‑enhanced CT or MRI – Detects primary tumors and metastatic disease (most commonly liver).
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – Gold standard for locating neuroendocrine tumors.

3. Functional Assessment of Diarrhoea

• Fecal fat quantification – Detects steatorrhea from malabsorption.
• Stool electrolytes and osmolar gap – Distinguish secretory from osmotic diarrhoea.
• 24‑hour gastric acid output (rarely used) – Confirms hyper‑secretion.

Guidelines from the Mayo Clinic and the NIH recommend confirming both biochemical and radiologic evidence before initiating definitive therapy.

Treatment Options

Treatment aims to control acid hypersecretion, manage diarrhoea, and address the underlying tumour. A multidisciplinary approach (gastroenterology, surgery, oncology, nutrition) yields the best outcomes.

Medical Management

• High‑dose Proton‑Pump Inhibitors (PPIs) – Omeprazole 40–80 mg daily, pantoprazole 80 mg daily, or equivalent; these are the cornerstone for acid suppression.
• Histamine‑2 receptor antagonists (H2‑blockers) – May be added for breakthrough symptoms.
• Somatostatin analogues (e.g., octreotide or lanreotide) – Reduce gastrin secretion and can shrink tumour burden in metastatic disease.
• Potassium and magnesium replacement – Oral or intravenous repletion for electrolyte abnormalities caused by chronic diarrhoea.
• Antidiarrhoeal agents – Loperamide or diphenoxylate‑atropine for symptomatic relief, but they do not treat the underlying acid excess.
• Pancreatic enzyme supplementation – If malabsorption is evident, enteric‑coated lipase preparations improve stool consistency.
• Antibiotics for SIBO – Rifaximin 550 mg twice daily for 2 weeks, if breath testing confirms bacterial overgrowth.

Surgical and Oncologic Treatment

• Localized tumor resection – Enucleation or pancreaticoduodenectomy (Whipple) for isolated gastrinomas; offers potential cure.
• Hepatic metastasis management – Options include hepatic resection, radiofrequency ablation, or hepatic arterial embolization.
• Targeted therapies – Everolimus or sunitinib for progressive metastatic neuroendocrine tumours.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive disease (per NCCN guidelines).

Home and Lifestyle Measures

• Stay well‑hydrated; oral rehydration solutions with electrolytes are preferred.
• Eat small, frequent meals low in fat and spice to minimise acid stimulus.
• Avoid alcohol, caffeine, and nicotine, which increase gastric secretion.
• Maintain a symptom diary (stool frequency, diet, medication timing) to share with your care team.

Prevention Tips

Because ZES is a tumour‑driven condition, primary prevention is not feasible. However, patients can reduce the impact of diarrhoea and limit complications:

• Adhere strictly to prescribed PPI dosing—under‑dosing can lead to breakthrough acid and diarrhoea.
• Regular monitoring of gastrin levels, electrolytes, and vitamin D/calcium status.
• Vaccinations for hepatitis B and influenza (especially if receiving systemic chemotherapy).
• Annual bone density screening – early detection of osteoporosis.
• Prompt treatment of infections – especially C. difficile, as antibiotics can exacerbate diarrhoea.
• Weight‑bearing exercise – helps maintain bone health and overall well‑being.

Emergency Warning Signs

---

© 2026 HealthInfoNet. All information is for educational purposes and does not replace professional medical advice. Consult a qualified healthcare provider for personalized diagnosis and treatment.

```